16 or 32 channel sense head coil

MRI was performed on a 3T scanner (Achieva and Ingenia; Philips Healthcare, Best, The Netherlands) with a 16- or 32-channel SENSE Head Coil (Philips Healthcare). The MRI protocol included diffusion-weighted imaging (DWI), T1-, and T2-weighted gradient echo axial imaging, and T1-weighted sagittal imaging.
To delineate the structures within the labyrinth, additional sequences were applied to include 3D heavily T2- (T2-weighted volume isotropic turbo spine-echo acquisition, VISTA), 3D contrast-enhanced T1, and 3D contrast-enhanced fluid-attenuated inversion recovery (FLAIR) images in all patients. In addition, when the differentiation between ILS and labyrinthitis was not evident, a quantitative analysis of the signal intensity was performed for detection of ILS by two neuroradiologists who were blinded to the clinical findings. ILS was diagnosed radiologically when the lesion showed enhancement on 3D contrast-enhanced T1-weighted or 3D contrast-enhanced FLAIR images, in combination with a filling defect and replacement of the normal high-signal intensity fluid on 3D VISTA (1 (link), 11 (link)). The detailed methods for imaging and analysis protocols were described elsewhere (11 (link)). We also classified ILS according to the tumor location in the labyrinth using the previously described methods (1 (link), 18 (link)).

Temporal bone MRI was acquired using a 3 T scanner (Achieva and Ingenia, Philips Healthcare, Best, the Netherlands) with a 16- or 32-channel SENSE head coil (Philips Healthcare). We acquired three-dimensional (3D) heavily T2-weighted images (T2WI), two-dimensional (2D) pre-contrast T1-weighted images (T1WI), 3D pre-contrast fluid-attenuation inversion recovery images (preFLAIR), 3D post-contrast T1WI (postT1WI), and 3D post-contrast FLAIR images (postFLAIR). For contrast-enhancement, 0.1 mmol/kg of gadobutrol (Gadovist, Bayer Schering Pharma AG, Berlin, Germany) was intravenously injected as a bolus. PostT1WI and postFLAIR were scanned approximately 2 min and 7 min post-injection, respectively. Whole-brain T2WI and FLAIR were obtained in all patients to exclude other brain pathologies. Detailed parameters of each sequence are summarized in Table S1.